Navigation Links
NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant
Date:3/4/2010

NEW YORK, March 4 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR). Under terms of the SRA, NeoStem will have the first option to license discoveries stemming from the project.

Funding from this grant will support the study of the potential of very small embryonic-like stem cells to form bone in an animal model and regenerate a critical sized bone defect using NeoStem's proprietary VSEL(TM) Technology. Very small embryonic-like stem cells are a heterogeneous population of stem cells found in adult bone marrow that have properties similar to those of embryonic stem cells. These cells have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilem
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeoStem Announces NY State License for Adult Stem Cell Collection
2. NeoStem to Present at Third Annual Stem Cell Summit in New York City
3. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
4. NeoStem Featured in WCBS-TV Health Watch Segment on Adult Stem Cells
5. NeoStem to Expand Stem Cell Collection Center Network to Florida
6. NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
7. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
8. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
9. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
10. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... IL (PRWEB) May 30, 2015 ... cutting-edge, novel research for bile duct cancer, announced ... launched Research Fellowship Program. , The ... outstanding scientists throughout the country to raise awareness ... funding will support research that opens new pathways ...
(Date:5/30/2015)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and ... BAX ) today announced data from PERSIST-1 – a ... treatment of myelofibrosis – in a late-breaking oral session ... Society of Clinical Oncology (ASCO), May 29-June 2, 2015 ... an investigational oral multikinase inhibitor with specificity for JAK2 ...
(Date:5/30/2015)... RARITAN, N.J. , May 30, ... two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show ... anti-CD38 monoclonal antibody – achieved an overall response ... as assessed by an independent review committee, in ... was consistent among the pre-specified subgroups based on ...
(Date:5/30/2015)... 2015  Caris Life Sciences® today announced the ... researchers identified biomarker changes, including key driver mutations, ... changes in response to therapy as the disease ... subset of a larger study analyzing 1,245 glioma ... These data utilizing Caris Molecular Intelligence®, the company,s ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... dream of competing together to race the fastest cars they ... group of 20 engineers, scientists and technicians from Ohio State ... is to win the $1 million dollar grand prize awarded ... , ,The Defense Advanced Research Projects Agency (DARPA) has ...
... Wis. -- Fiserv Inc., a provider ... Management, a portfolio management and investment accounting solution. ... trade execution, accounting, international settlement support and regulatory ... handle several accounting bases and closing dates and ...
... and community development specialist, presented a hopeful outlook for ... on Economic Development . Abstaining from morbid statistics and ... businesses in Wisconsin. , ,Wisconsin manufacturing suffered very little ... He cited that Wisconsin saw only a 9.1 percent ...
Cached Biology Technology:Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 2Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 3Optimistic Outlook For Manufacturing 2
(Date:5/29/2015)... , May 28, 2015 Research ... addition of the "Facial Recognition Market by ... - Global Forecast to 2020" report to ... have seen facial recognition technology become more efficient ... to gain traction and investment from the commercial ...
(Date:5/28/2015)... GLEN ALLEN, Va. , May 28, 2015 ... announced the release of a new report titled ... self-healing materials (reversible polymers, inorganic capsule and vascular ... self-healing coatings) will grow to around $2.7 billion ... latest deliverable from n-tech,s extensive coverage of smart ...
(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... are small, lungless amphibians that live in moist, forest ... serve as vital links in forest food chains; their ... predict the health of forest ecosystems. Now, researchers at ... size reflects forest habitat quality and can predict how ...
... intracellular particle tracking (simultaneous tracking of the motions ... and even individual molecules), that is an important ... search for appropriate medicines against certain diseases (including ... winner. Techniques proposed by all the participants, ...
... levels of air pollutants were nearly three times as likely ... of pollution exposure, report researchers at Columbia University Medical Center ... both increased dramatically in the past 30 years. The percentage ... in 1980 to 20% in 2008. Childhood asthma is up ...
Cached Biology News:Salamanders help predict health of forest ecosystems and inform forest management 29 and 60 ways of particle tracking 29 and 60 ways of particle tracking 3Obese children more susceptible to asthma from air pollution 2
Determin interaction of your protein with Echelons lipids...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... tubes are used to store 2.0 ml ... uniform walls for uniform heat transfer and ... caps. The O-rings are made of polyethylene ... from -55 to 150 degrees C. Supplied ...
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
Biology Products: